Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 130 entries
View as:

Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06140589 Org: User:
Start: 09/07/24 End: 12/31/26 Due: 12/31/27

Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06600841 Org: User:
Start: 10/01/24 End: 10/01/28 Due: 10/01/29

An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas

Phase: N/A Priority: Normal
NCT ID: NCT05928962 Org: User:
Start: 10/27/22 End: 10/31/24 Due: 10/31/25

Comparison of Short Term Outcomes Between Totally Laparoscopic and Laparoscopy-Assisted Distal Gastrectomy With Billroth-II Reconstruction and D2 Lymphadenectomy for Locally Advanced Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02365896 Org: User:
Start: 06/30/15 End: - Due: -

A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06614621 Org: User:
Start: 02/01/25 End: 12/01/28 Due: 12/01/29

Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06455046 Org: User:
Start: 10/11/23 End: 10/10/25 Due: 10/10/26

Effects of Mobile Medicine on Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT05049811 Org: User:
Start: 11/30/21 End: 06/30/22 Due: 06/30/23

A Diagnostic Nomogram for Predicting Vaginal Invasion in Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06039982 Org: User:
Start: 11/01/23 End: 11/01/26 Due: 11/01/27

Evaluating the Rationality of the International Guideline About Selective Coverage of Level Ib in CTV With NPC

Phase: N/A Priority: Normal
NCT ID: NCT04745741 Org: User:
Start: 05/01/21 End: 06/01/21 Due: 06/01/22

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06793917 Org: User:
Start: 04/01/25 End: 04/01/29 Due: 04/01/30

Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy Regimens

Phase: N/A Priority: Normal
NCT ID: NCT04089657 Org: User:
Start: 12/01/19 End: 12/01/21 Due: 12/01/22

Change the Dose Frequency of Controlled-Release Oxycodone to Refractory Pain

Phase: N/A Priority: Normal
NCT ID: NCT03639415 Org: User:
Start: 10/30/18 End: 03/30/21 Due: 03/30/22

PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM

Phase: N/A Priority: Normal
NCT ID: NCT06788171 Org: User:
Start: 03/01/25 End: 12/01/26 Due: 12/01/27

A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT06746545 Org: User:
Start: 02/01/25 End: 02/01/27 Due: 02/01/28

Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06197438 Org: User:
Start: 01/01/24 End: 04/01/25 Due: 04/01/26

The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05640726 Org: User:
Start: 05/01/23 End: 05/01/26 Due: 05/01/27

PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06078670 Org: User:
Start: 10/10/23 End: 06/30/26 Due: 06/30/27

CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06095154 Org: User:
Start: 01/01/25 End: 12/31/30 Due: 12/31/31

The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06242392 Org: User:
Start: 01/31/24 End: 07/01/26 Due: 07/01/27

The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction

Phase: N/A Priority: Normal
NCT ID: NCT06396585 Org: User:
Start: 08/01/24 End: 08/31/26 Due: 08/31/27

Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC

Phase: N/A Priority: Normal
NCT ID: NCT03222089 Org: User:
Start: 07/20/17 End: 07/20/20 Due: 07/20/21

Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05839470 Org: User:
Start: 11/19/23 End: 03/01/25 Due: 03/01/26

Opioid Titration With 12.5 ug/h Fentanyl Transdermal Patch vs Orally Morphine for Opioid-naïve Patients With Moderate Cancer Pain

Phase: N/A Priority: Normal
NCT ID: NCT04533243 Org: User:
Start: 09/01/20 End: 08/31/22 Due: 08/31/23

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05675033 Org: User:
Start: 01/10/23 End: 01/10/24 Due: 01/10/25

Intensity Modulated Radiotherapy in Recurrent T1-2 Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02113423 Org: User:
Start: 01/31/96 End: 03/31/11 Due: 03/31/12